Loxo Edges Closer To Commercial Market With Larotrectinib, But Diagnostic Challenge Persists

Loxo impressed at ASCO last year with larotrectinib, which has now been accepted by FDA for priority review with a PDUFA date of Nov. 26, and the oncology drug developer could shine again this year. If approved, however, larotrectinib could launch ahead of its companion diagnostic.